logo-loader
viewT2 Biosystems

T2 Biosystems shares rocket as it unveils worldwide licensing agreement for coronavirus test

It will adapt the licensed coronavirus assay, which was developed by New Jersey's Center of Discovery and Innovation, to run on the company's T2Dx Instrument

T2 Biosystems -
T2 Biosystems said that by adding this complementary test to the T2Dx platform, the firm will be able to provide a comprehensive assessment of patients suspected of primary or secondary infections associated with coronavirus, when timely results are most critical

Shares in T2 Biosystems Inc (NASDAQ:TTOO) skyrocketed in New York on Wednesday after the diagnostics group struck a worldwide licensing agreement for a new coronavirus test which provided answers quickly.

Under the terms of the deal, the firm will adopt the licensed coronavirus assay, which was developed by New Jersey's Center of Discovery and Innovation at Hackensack Meridian Health, to run on the company's T2Dx Instrument.

T2 Biosystems stock soared 125% to $0.88 each in morning trade on Wednesday, before easing back to $0.74, up 88.5%.

READ: Shares of T2 Biosystems soar on positive data supporting T2Lyme Panel

The ongoing disease crisis has accelerated the need for worldwide testing, with nearly 335,000 cases of coronavirus globally and a death toll of more than 14,500.

In the USA, more than 33,400 cases have been reported across all 50 states, with 400 deaths, according to the Centers for Disease Control and Prevention (CDC).

T2 Biosystems said that by adding this complementary test to the T2Dx platform, the firm will be able to provide a comprehensive assessment of patients suspected of primary or secondary infections associated with coronavirus when timely results are most critical.

"This agreement combines our FDA-cleared T2Dx platform with our joint scientific expertise to benefit patients at risk for both primary coronavirus infections, as well as associated secondary infections that may lead to sepsis,” said John Sperzel, the CEO of T2 Biosystems.

"The ability to detect coronavirus and associated secondary bacterial or fungal infections that may lead to sepsis, without the need to wait days for a diagnostic result, allows clinicians to achieve targeted therapy faster, and can lead to reduced length of stay in the intensive care unit, freeing up beds for incoming patients."

Hackensack Meridian Health is a not-for-profit health care organization — the largest, most comprehensive and integrated health care network in New Jersey.

Contact the author at [email protected]

Quick facts: T2 Biosystems

Price: 0.51 USD

NASDAQ:TTOO
Market: NASDAQ
Market Cap: $51.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Algernon Pharmaceuticals receives positive feedback from...

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver to discuss the company receiving positive feedback from Health Canada on the Company’s plan for a Phase Two COVID-19 clinical study in Canada, with its repurposed drug...

4 hours, 7 minutes ago

2 min read